

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE
HIGHLY SPECIALISED TECHNOLOGIES EVALUATION PROGRAMME

Equality impact assessment – Scoping

HST
Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene (review of HST3)
ID1642

The impact on equality has been assessed during this appraisal according to the principles of the NICE Equality scheme.

1. Have any potential equality issues been identified during the scoping process (draft scope consultation and scoping workshop discussion), and, if so, what are they?

Several consultees raised the issue of ease of access for patients from all areas of the country to attend specialist centres for people with Duchenne muscular dystrophy.

2. What is the preliminary view as to what extent these potential equality issues need addressing by the Committee?

The committee will be made aware of issues related to ease of access to treatment in relation to people with Duchenne muscular dystrophy.

3. Has any change to the draft scope been agreed to highlight potential equality issues?

No changes have been made.

4. Have any additional stakeholders related to potential equality issues been identified during the scoping process, and, if so, have changes

to the matrix been made?
No additional stakeholders have been identified.

Approved by Associate Director (name): Jasdeep Hayre

Date: 7 January 2022